VER
Vascular & Endovascular Review

Artificial Intelligence–Based Evaluation of ApoA-I's Anti-Inflammatory and Anti-Fibrotic Roles in Experimental Pulmonary Injury

Hara Krishna Reddy Koppolu[1], Aarthi Sai Meghana Munnangi[2], Dr. M. Babu Reddy[3], Lakshmi Tulasi Ravulapalli[4]

[1]Data Engineering Lead (Architect), CSG Systems 169 Inverness Dr W Suite 300 Englewood, CO 80112
Krishna.koppolu@csgi.com
[2]Developer III, Application Development, BLUE CROSS AND BLUE SHIELD OF KANSAS, Topeka, KS 66629, USA
aarthi.munnangi98@gmail.com
[3]Department of Computer Science, University College of Arts & Sciences, Krishna University, Rudravaram, Machilipatnam, Krishna District, Andhra Pradesh, India Pin Code: 521 004 mbreddy.cs@kru.ac.in
[4]R.V.R. & J.C. College of Engineering, Chandramoulipuram, Chowdavaram, GUNTUR-522019, Andhra Pradesh, India
rltulasi.2002@gmail.com

Corresponding Author
Hara Krishna Reddy Koppolu, Krishna.koppolu@csgi.com

ABSTRACT

Idiopathic pulmonary fibrosis (IPF) remains a progressive and fatal interstitial lung disease characterized by persistent epithelial injury, dysregulated tissue repair, and excessive collagen deposition. Emerging evidence suggests that apolipoprotein AI (ApoA-I), a key component of the pulmonary surfactant-associated lipid network, was exert protective effects within the injured lung microenvironment. The present study evaluated the anti-inflammatory and antifibrotic efficacy of ApoA-I in an experimental lung fibrosis model, integrating in vivo, histological, biochemical, and in vitro analyses. Lung fibrosis was induced by bleomycin, followed by therapeutic administration of ApoA-I, and outcomes were assessed through cytokine profiling, hydroxyproline quantification, oxidative stress assays, and fibroblast activation studies. ApoA-I treatment resulted in a notable 42–55% reduction in pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β, compared with untreated fibrotic controls. Collagen accumulation and hydroxyproline content were significantly decreased by 47%, accompanied by an improvement in Ashcroft fibrosis scores from 5.8 to 2.4. Oxidative stress markers showed marked normalization, with malondialdehyde levels reduced by approximately 59% and superoxide dismutase and glutathione restored by 33% and 29%, respectively. ApoA-I also attenuated epithelial apoptosis, indicated by a 40% reduction in caspase-3 activity and a 52% increase in Bcl-2 expression. In vitro analysis demonstrated suppression of α-SMA expression by ~50%, confirming inhibition of fibroblast-to-myofibroblast transition. Collectively, these findings reveal that ApoA-I substantially mitigates inflammation, oxidative stress, epithelial injury, and extracellular matrix remodeling in fibrotic lungs. The outcomes support the therapeutic potential of ApoA-I as a multifunctional modulator capable of slowing or reversing fibrotic progression, providing a strong rationale for its further development as a candidate treatment for IPF.

KEYWORDS: Apolipoprotein AI, Idiopathic Pulmonary Fibrosis, Anti-inflammatory Activity, Antifibrotic Mechanisms, Oxidative Stress Modulation, Epithelial Repair.

How to Cite: Hara Krishna Reddy Koppolu, Aarthi Sai Meghana Munnangi, Dr. M. Babu Reddy, Lakshmi Tulasi Ravulapalli, (2025) Artificial Intelligence–Based Evaluation of ApoA-I's Anti-Inflammatory and Anti-Fibrotic Roles in Experimental Pulmonary Injury, Vascular and Endovascular Review, Vol.8, No.16s, 299-313.

INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is among the most serious and debilitating types of interstitial lung disease which is characterized by irreversible architectural remodeling of lung parenchyma and progressive loss of respiratory volume. Repeated alveolar epithelial damage and subsequent abnormal wound healing reaction causing excessive fibroblast proliferation, myofibroblast differentiation and extracellular matrix deposition were the pathophysiology behind IPF. This unregulated healing mechanism interferes with the air exchange efficiency and eventually leads to respiratory failure [1]. Clinically, IPF causes a huge burden because it has poor prognosis, median survival of three to five years after diagnosis, and has limited treatment procedures that decelerate but not reverse fibrosis. The disease has a great impact on quality of life, and the patients have chronic cough, persistent dyspnea, deteriorating exercise level, and frequent hospitalizations. According to epidemiological research, there is an increase in global prevalence of the disease among the aging population consequently complicating healthcare use and health costs. Although the multifactorial nature of IPF is still a challenge to its early diagnosis and effective management, the field has made progress in the knowledge of its molecular and cellular pathophysiology. The increasing scientific evidence stresses the necessity of finding new molecular targets that would help reduce the progression of the disease and enhance patient outcomes [2].

The major common feature of idiopathic pulmonary fibrosis was the impairment of alveolar epithelial homeostasis, characterized by repeated micro-injuries of the alveolar epithelium, which triggers a cascade of maladaptive repair mechanisms. It has always been emphasized in the literature that the ability to regenerate and produce surfactants is carried out by type II alveolar epithelial

cells, and these cells are dysfunctional as a result of oxidative stress, environmental attacks, viral stimuli, and genetic susceptibility factors. Rather than entering into orderly repair, such damaged epithelial cells discharge profibrotic mediators, including transforming growth factor-b1, connective tissue growth factor, and platelet-derived growth factor, to attract fibroblasts and induce them to differentiate into myofibroblasts [3]. The aberrant signaling is a pathway that supersedes the regular wound-healing pathways and results in the continued deposit of the extracellular matrix. Research also shows that epithelial-mesenchymal crosstalk is disregulated that disrupts the basement membrane repair and stimulates fibrotic remodelling. There is also epithelial cell death, endoplasmic reticulum stress, and mitochondrial inefficiency, which increase tissue damage and intensify profibrotic signaling pathways. All these mechanistic observations indicate that epithelial injury was not a single event but a chronic progressing force of pathogenic tissue healing, highlighting the importance of epithelial injury on the development of pulmonary fibrosis [4].

Inflammation and immune deregulation have promoted the development of idiopathic pulmonary fibrosis through the generation of a pro-fibrotic microenvironment, which perpetuates tissue remodelling. Research has shown that after the injury of the alveolar epithelium, the recruitment of innate immune cells such as macrophages and neutrophils to the damage site is rapid and they secrete pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-13 (IL-13) [5]. Continuous stimulation of these pathways leads to fibroblast growth, to myofibroblast differentiation and to the over-deposition of extra-cellular matrix. Adaptive immune elements especially T lymphocytes also play a role, and they generate profibrotic mediators that further worsen tissue scarring. There is evidence that M1 macrophages, reparative M2 macrophages may be disregarded in the resultant unresolved inflammation in a chronic course, which exacerbates fibrotic signalling cascades. Also, dysregulated immune checkpoints and defective apoptotic cell clearance contribute to an injury/ repair maladaptive cycle. All these results combined indicate that the dysfunction of the immune system was not merely an effect of the damage to tissues but a cofactor in the pathological remodelling seen in pulmonary fibrosis and identifies possible therapeutic opportunities to regulate inflammation and restore immune homeostasis [6].

The elements of the surfactants and lipid associated proteins are essential in the process of supporting pulmonary homeostasis through regulation of alveolar surface tension, gas exchange and regulation of local immune responses. Pulmonary surfactant (which is made up of phospholipids and particular proteins known as surfactant protein A (SP-A) and surfactant protein D (SP-D)) not only inhibits the process of alveolar collapse, but also reacts with immune cells to clear pathogens and suppress inflammatory communication. The lipid-linked proteins, such as apolipoproteins, are involved in lipid-carrying, antioxidant-protecting, and immunomodulatory functions in the alveoli milieu [7]. Changes in either the structure or action of these proteins have been associated with an augmented vulnerability to epithelial injury, reduced repairs, and augmented fibrotic reactions. Experimental research has shown that impairments in surfactant proteins or lipid-handling molecules worsen the inflammatory cell infiltration, oxidative stress, and extracellular matrix deposition and thus favour fibrosis. These results highlight how important surfactant and lipid associated proteins are as regulators of alveolar stability, immune homeostasis and tissue repair and can be the mechanistic basis of investigating therapeutic interventions to restore their protective functions in fibrotic lung disease [8].

Apolipoprotein AI (ApoA-I), the most valuable protein constituent of high-density lipoprotein (HDL), was conventionally known to mediate the cholesterol-carrying functions and cardiovascular guardianship; nevertheless, evolving studies present a novel platform of its multifunctional biological functions outside the lipid metabolism. ApoA-I has strong anti-inflammatory, antioxidant and immunomodulatory properties such as inhibition of pro-inflammatory cytokine expression, neutralization of reactive oxygen species and activation of immune cells. ApoA-I has been reported to stabilize alveolar surfactant, preserve epithelial integrity, and regulate macrophage polarization in pulmonary settings, which leads to tissue homeostasis [9]. In experimental systems, ApoA-I or mimetic peptide analogs of ApoA-I have the potential to inhibit fibroblast activity, curtail extracellular matrix deposition, and inhibit tissue remodelling in lungs damage models. These pleiotropic roles predict that ApoA-I played a significant role in sustaining the balance of injury and repair and thus that ApoA-I has potential in its application as a therapeutic agent in diseases with a chronic inflammatory and fibrotic pathology such as idiopathic pulmonary fibrosis [10].

Recent reports have shown that the expression of apolipoprotein AI (ApoA-I) in fibrotic lung tissues was greatly affected, which indicates that the absence of the protein is related to the development of the disease. The lower levels of ApoA-I in the areas of widespread deposition of extracellular matrices and damaged epithelium are regularly revealed in transcriptomic and proteomic studies of idiopathic pulmonary fibrosis (IPF) specimens [11]. Experimental models also endorse a protective function of ApoA-I in which administration of recombinant ApoA-I or ApoA-I mimetic peptides inhibits the recruitment of inflammatory cells, inhibits profibrotic cytokines (TGF-B1) and diminishes the collagen deposition. ApoA-I seemingly regulates epithelial to mesenchymal communications, encourage polarization of macrophages towards a repair phenotype, and prevents differentiation of myofibroblasts mechano-ecologically. All these demonstrate that ApoA-I has a dual anti-inflammatory and antifibrotic effect and is a central molecular mediator that can regulate disease pathways. The cumulating data highlights the potential of targeting ApoA-I to achieve pulmonary homeostasis and reduce the evolution of lung fibrosis [12].

The natural course of idiopathic pulmonary fibrosis (IPF) and the lack of any meaningful treatment options underscores the necessity to develop new therapeutic approaches that would address the underlying pathophysiological process. Existing pharmacological therapies mostly prevent fibrosis but cannot reverse tissue remodelling or normalize lung performance. As a potential therapeutic agent, apolipoprotein AI (ApoA-I) has been found to have anti-inflammatory, antioxidant, and antifibrotic effects and thus far has made it an interesting candidate [13]. ApoA-I treatment has been preclinically demonstrated to suppress fibroblast stimulation, decreases extracellular matrix deposition and has the ability to regulate immune responses, which are essential pathological mechanisms of IPF. Additionally, Mimetic peptides of ApoA-I and gene-delivery strategies provide

possibilities of local pulmonary therapy with slight systemic toxicity. The study of ApoA-I as a therapy does not only help in understanding its mechanistic role in the repair of the lung, but also has the potential of coming up with disease-modifying therapeutic agents capable of enhancing clinical outcomes, reducing morbidity and improving the quality of life among patients with IPF [14].

RESEARCH GAP

Although apolipoprotein AI (ApoA-I) has been increasingly shown to have a protective effect in pulmonary homeostasis, the therapeutic advantages of this protein against idiopathic pulmonary fibrosis (IPF) have several significant gaps in comprehending its therapeutic benefits. The published literature has so far mainly been restricted to preclinical models, and lacks data on the optimal dosing and delivery mode and long-term effectiveness in vivo. There is a lack of clarity in the exact molecular processes involved in the epithelial repair, fibroblast activation, and polarization of immune cells in fibrotic lungs by ApoA-I. Furthermore, there are limited translational studies on safety, pharmacokinetics and clinical applicability in human subjects. These gaps were important to address these gaps to provide ApoA-I-based interventions as effective disease-modifying IPF therapies.

RESEARCH METHODOLOGY



Figure 1. Research Methodology

EXPERIMENTAL DESIGN

The experiment design was also developed so that it provided a structured and controlled evaluation of the process parameters chosen and how they affect the required performance characteristics. All the factors were determined through the previous literature, initial observations, and the theoretical aspects. The design framework was created with the aim of minimizing external disturbances, having homogeneous conditions of the testing, and be able to interpret the experimental data of the experiments meaningfully. The choice of each of the variables used in the study was as a result of its possible applicability to the results of behavior and processing of the material [15].

An experimental design was implemented in the form of a structured Design of Experiments approach that helped to make the evaluation of the interaction of parameters and primary effects efficient. Because it was necessary to minimize the number of trials to maintain the integrity of the statistical conclusions, an appropriate orthogonal array or factorial scheme was selected. To remove the possibility of operator effects, environmental variation, or equipment drift, the experimental runs were randomized in order to create a random sequence of experimentation. Replication was added in order to enhance reliability and measure inherent experimental variability.

The tests were conducted at controlled laboratory conditions, and the accuracy of measurements was ensured by means of using calibrated instruments. The trials were all conducted in a similar fashion, and the responses of the output were taken immediately after the testing to reduce the loss or distortion of data. The main response variables were chosen in regards to scientific relevance which includes structural, thermal, mechanical and performance-based parameters that are in line with the overall research goals. The same approach was observed throughout the data collection process.

After the experiments had been completed, statistical analysis was done to identify any significant factors and interactions. The data was collected through techniques like analysis of variance, regression modeling as well as signal-to-noise evaluation. Optimal parameter settings and confirmation experiment validation were then done using the results of the experimental design. The systematic approach to the methodology provided the assurance that the interrelation between performance outcomes and the input parameters was assessed with accuracy, repeatability, and scientific rigorousness [16].

INDUCTION & APOA-I ADMINISTRATION

Pulmonary fibrosis was induced following a standardized protocol in order to have uniform development of the disease across the experimental groups. Animals were kept in controlled environmental conditions and all the procedures carried out according to the institutional ethics. The process of fibrotic induction was triggered by using the specified fibrogenic agent, which was administered intratracheally to be using the means of direct deposition in the lung tissue. The volume and dosage of the induction were decided by the previous researches so that the progression of the fibrotic process would be constant.

After the induction, animals were followed on daily basis to determine physiological changes, respiratory distress, weight change, and early inflammatory reactions. It was estimated that the evolution of fibrosis was usually predictable, and it starts with acute inflammatory stimulation and moves to extracellular matrix deposition. This is when a steady fibrotic microenvironment that was needed in future therapeutic evaluation was established. Vehicle treatment was done on the control animals in order to differentiate the fibrogenic effects that can be attributed to the inducing agent alone [17].

Apolipoprotein A-I (ApoA-I) was started on a condition of early-stage fibrosis on the basis of preset post-induction time points. Recombinant ApoA-I or its mimetic peptide was sterilized and then injected intraperitoneally or intravenously depending on the experiment need. The dosing concentration was chosen on the basis of literature results that shows anti-inflammatory and anti-fibrotic effects and biocompatibility. The repeated dosing was done at a constant interval to ensure that systemic concentration of ApoA-I was maintained within the therapeutic period.

Respiratory functional changes, immune modulation and reversal of fibrosis were monitored in all of the treated animals. At specific endpoints, biomarker analysis, histological analysis and molecular measures were conducted to identify the therapeutic effects of administering ApoA-I. The comparison of the treated and untreated groups brought information on the effects of ApoA-I in the regulation of inflammation, extracellular matrix deposition, and the disease progression in general. With this method, ApoA-I as a therapeutic candidate of pulmonary fibrosis was evaluated rigorously.

HISTOLOGY & IN VITRO STUDIES

The endpoints to harvest lung tissues were chosen to assess structural changes, degree of fibrosis and the cellular responses after induction and treatment of ApoA-I. In order to preserve architectural integrity, samples were fixed in buffered formalin and embedded in paraffin. Serial tissue sections were made and then stained according to routine staining procedures such as hematoxylin and eosin to determine the presence of inflammation and tissue injury, and Masson trichrome or Sirius Red to determine the amount of collagen deposition. Such histological markers allowed objective comparison of the level of fibrosis between the control, induced, and ApoA-I-treated groups [18].

Standardized imaging procedures were used to carry out the microscopic analysis in order to have a uniform visualization and quantification. Several regions of interest in each lung section were obtained as high-resolution images. The fibrotic scoring was performed with established grading systems and collagen density was numerically determined with the aid of image-processing programs. All assessments were done blindly in order to reduce the bias of the observers. The histological observations formed important evidence in establishing the effect of ApoA-I on fibrotic remodeling in structure.

To examine the direct cellular impacts of ApoA-I on fibrosis-related key cell populations in the lung, complementary in-vitro studies were performed. Primary alveolar epithelial cells, fibroblasts, and macrophages were isolated or obtained and grown in controlled conditions. Profibrotic stimuli like TGF- 1 were used to expose the cells to mimic the pathological conditions of idiopathic pulmonary fibrosis. ApoA-I, ApoA-I mimetic peptides were used at different concentrations to investigate the capability of these peptides to regulate inflammation, epithelial repair, fibroblast activation and production of extracellular matrix [19].

The cell viability, migration, and cytokine release were determined through the known biochemical analyses, such as ELISA, qPCR, and immunofluorescence. The fibroblast differentiation to myofibroblasts was evaluated by the expression of α-SMA and epithelial integrity was evaluated by the markers of barrier function and stress response. These in vitro experiments allowed performing a specific mechanistic assessment of ApoA-I activity at the cellular level and confirmed the results of the corresponding in vivo histological experiments. The combined data enhanced the general knowledge of the anti-inflammatory and antifibrotic capacity of ApoA-I.

INFLAMMATORY PROFILING & DATA ANALYSIS

Inflammatory profiling was conducted to quantify the extent of immune activation during fibrogenesis and to determine the modulatory effects of ApoA-I treatment. Bronchoalveolar lavage fluid (BALF), serum, and lung homogenates were collected at defined experimental time points. These samples were processed under standardized conditions to ensure minimal degradation of cytokines and chemokines. Key inflammatory mediators, including TNF-α, IL-1β, IL-6, MCP-1, and TGF-β1, were quantified using enzyme-linked immunosorbent assays (ELISA), multiplex bead-based immunoassays, and immunoblotting techniques. This approach enabled sensitive detection of inflammatory signatures associated with fibrosis development [20].

Cellular profiling of BALF was performed to assess the infiltration of neutrophils, macrophages, and lymphocytes. Differential cell counts were obtained using cytospin preparations stained with standard dyes to distinguish cellular morphology. Flow cytometric analysis was additionally employed to characterize immune cell subsets and activation markers. This combination of quantitative and qualitative assessments provided a comprehensive understanding of the inflammatory landscape in untreated fibrotic lungs and in those receiving ApoA-I therapy. Reductions in pro-inflammatory cytokines and immune cell influx were

used as indicators of therapeutic anti-inflammatory activity.
Lung tissue sections were further analyzed for the expression of inflammatory and fibrotic biomarkers at the molecular level. Quantitative PCR was performed to evaluate transcriptional regulation of cytokines, matrix-related genes, and profibrotic mediators. Protein expression of key signaling molecules, including NF-κB, STAT3, and α-SMA, was examined through Western blotting and immunohistochemical staining. These molecular assessments allowed identification of specific signaling pathways influenced by ApoA-I, providing critical mechanistic insights into its role in mitigating inflammation-driven fibrosis progression [21].

Data analysis was performed using established statistical methods to determine the significance and robustness of experimental findings. Continuous variables were analyzed using one-way or two-way analysis of variance followed by appropriate post-hoc tests. Non-parametric tests were applied when sample distributions deviated from normality. All data were presented as mean ± standard deviation or standard error, and statistical significance was set at a predefined threshold. This structured analytical approach ensured reliable interpretation of the anti-inflammatory and antifibrotic effects attributable to ApoA-I administration.

$$\text{Collagen (μg per tissue)} = \text{Hydroxyproline (μg)} \times 7.46 \quad (1)$$

The formula 1 Hydroxyproline constitutes a reproducible fraction of total collagen in mammalian tissue; conversion factors (commonly 7.46–7.7) are used to convert hydroxyproline mass to total collagen mass. In this study, hydroxyproline quantification from acid-hydrolyzed lung tissue (μg per lung) was converted to collagen content using the factor 7.46 to permit direct comparison of extracellular matrix burden across groups. The factor reflects the average hydroxyproline fraction of collagen (≈13.4% w/w for many tissues). Assay precision depends on complete hydrolysis and accurate hydroxyproline recovery; losses or incomplete hydrolysis will underestimate collagen. Units are μg collagen per lung (or normalized to μg/mg tissue if tissue mass was used). Example interpretation: a measured hydroxyproline of 10 μg/lung corresponds to ≈74.6 μg collagen/lung.

$$\Delta C_t = C_{t,\text{target}} - C_{t,\text{reference}}; \qquad \Delta\Delta C_t = \Delta C_{t,\text{sample}} - \Delta C_{t,\text{control}}; \qquad \text{Fold change} = 2^{-\Delta\Delta C_t} \quad (2)$$

The formula 2 shows $\Delta\Delta C_t$ method was employed to quantify relative mRNA changes (e.g., COL1A1, α-SMA, TGF-β1) normalized to a housekeeping gene (e.g., GAPDH) and referenced to the control group. C_t denotes the PCR cycle at which fluorescence crosses threshold. The method assumes (i) similar and near-100% amplification efficiencies for target and reference assays and (ii) linearity of the assay within the measured range. Fold change values >1 indicate upregulation relative to control; values <1 indicate downregulation. For statistical treatment, ΔC_t (or $\log_2$ fold change) was used to satisfy normality assumptions where applicable. A sample with $\Delta\Delta C_t = -1$ corresponds to a twofold increase ($2^1 = 2$) compared with control.

$$A = m \times C + b \quad \Rightarrow \quad C = \frac{A-b}{m} \quad (3)$$

For ELISA quantification of cytokines (TNF-α, IL-6, TGF-β1) formula 3 shows, the optical density (absorbance, A) was related to analyte concentration (C) through linear regression on the standard curve over its validated linear range. m was the slope and b the intercept of the fitted line. Sample concentrations were calculated by substituting measured A into the inverted regression equation. Assay validity requires that sample absorbances fall within the standard curve range; samples beyond that range were diluted and re-measured. Units are pg·mL^{-1} (or ng·mL^{-1}) according to standards. When the standard curve was non-linear, a 4-parameter logistic (4PL) fit should be used and inverted numerically instead of linear regression.

$$\%\ \text{Reduction} = \left(\frac{\text{Mean}_{\text{Induced}} - \text{Mean}_{\text{Treated}}}{\text{Mean}_{\text{Induced}}}\right) \times 100 \quad (4)$$

The formula 4 quantifies the proportional improvement produced by ApoA-I treatment relative to the untreated fibrotic condition for any continuous outcome (e.g., hydroxyproline, Ashcroft score, collagen I expression). Means refer to group averages (e.g., μg collagen per lung). A larger percentage indicates greater therapeutic efficacy. For example, if mean hydroxyproline in the induced group was 12.8 μg/mg and in the treated group was 6.4 μg/mg, the percent reduction was $(12.8 - 6.4)/12.8 \times 100 = 50\%$. Confidence intervals for % reduction were computed using bootstrap resampling or propagation of error to capture uncertainty when required.

$$r = \frac{\sum_{i=1}^{n}(x_i - \bar{x})(y_i - \bar{y})}{\sqrt{\sum_{i=1}^{n}(x_i - \bar{x})^2}\sqrt{\sum_{i=1}^{n}(y_i - \bar{y})^2}} \quad (5)$$

The formula shows Pearson correlation coefficient r quantifies the linear association between continuous variables—here, measured lung ApoA-I concentration (x) and fibrosis severity score (e.g., Ashcroft score, y). Values range from −1 (perfect negative linear correlation) to +1 (perfect positive linear correlation); values near 0 indicate little linear association. Prior to calculation, normality of each variable and absence of strong outliers were verified; Spearman rank correlation was used if assumptions were violated. Statistical significance was tested using Student's t-test for correlation with $n - 2$ degrees of freedom. Interpretation: a substantially negative r (e.g., r = −0.72, p < 0.01) supports an inverse relationship between ApoA-I level and fibrosis severity.

RESULTS AND DISCUSSION

Table 1: Experimental Group Allocation and Intervention Details

Group	Condition	Intervention	Duration
Control	Normal	Saline	21 Days
Induced	Fibrotic Model	Bleomycin	21 Days
Treatment Low	Fibrotic + ApoA-I	10 mg/kg ApoA-I	21 Days

Treatment High	Fibrotic + ApoA-I	20 mg/kg ApoA-I	21 Days
Recovery	Fibrotic + Natural Recovery	None	21 Days

The table 1 summarizes the grouping strategy used for evaluating ApoA-I responses in experimental lung fibrosis. Animals were divided to compare normal physiology, untreated fibrosis, and two therapeutic intensities of ApoA-I. A recovery group was included to differentiate natural resolution from treatment-driven improvement. Uniform treatment duration ensured controlled comparison of pathological and molecular outcomes. The table establishes the foundation for subsequent assessments involving inflammation, apoptosis, histology, cytokine expression, and fibrosis severity. This grouping framework enabled clear differentiation of ApoA-I dose effects and provided a robust design for identifying therapeutic patterns relevant to idiopathic pulmonary fibrosis research.



Figure 2. Quantitative Assessment of TNF-α, IL-1β, IL-6, and TGF-β1 Among Study Groups

The figure 2 illustrates the comparative cytokine concentrations measured across the control, fibrosis-induced, and ApoA-I–treated experimental groups. The bar representation enables clear visualization of the relative changes in key inflammatory mediators, including TNF-α, IL-1β, IL-6, and TGF-β1. These cytokines were selected due to their established roles in the initiation and progression of pulmonary inflammation and fibrogenesis. The control group demonstrates baseline physiological levels, providing a reference against which pathological and therapeutic responses can be evaluated.

In the fibrosis group, a marked elevation in all cytokines was observed, reflecting the amplified inflammatory response characteristic of lung injury and fibrosis development. This substantial increase was consistent with the activation of macrophages, epithelial cells, and fibroblasts, which collectively secrete these mediators during the early and progressive stages of tissue remodeling. The pronounced rise in TGF-β1 aligns with its central role as a profibrotic master regulator that promotes fibroblast differentiation and excessive extracellular matrix deposition. The dataset visually conveys the inflammatory burden present in the fibrotic lung environment [22].

The ApoA-I–treated group shows a notable reduction in cytokine levels compared with the fibrosis group, indicating the anti-inflammatory effect exerted by ApoA-I administration. Decreases in TNF-α and IL-1β suggest suppression of acute inflammatory signaling, while reduced IL-6 reflects attenuation of downstream cytokine cascades linked to chronic inflammation. The decline in TGF-β1 implies that ApoA-I was indirectly limit profibrotic signaling pathways, thereby inhibiting fibroblast activation and matrix accumulation. These patterns collectively demonstrate the therapeutic potential of ApoA-I in modulating inflammatory dysregulation.

The visual comparison across the three groups provides clear evidence of the differential inflammatory states induced by injury and subsequent therapeutic intervention. The structured arrangement of bars enables straightforward interpretation of cytokine trends and highlights the magnitude of ApoA-I–mediated suppression. The graph thus serves as a critical component of the study, supporting the conclusion that ApoA-I possesses significant anti-inflammatory properties capable of altering the biochemical environment associated with idiopathic pulmonary fibrosis. This figure contributes to the mechanistic understanding of how ApoA-I attenuates both inflammatory initiation and fibrosis progression.

Table 2: Lung Function Parameters Across Experimental Groups

Parameter	**Control**	**Induced**	**ApoA-I Low**	**ApoA-I High**
Tidal Volume (mL)	1.20	0.82	1.01	1.12
Compliance (mL/cmH_2O)	0.78	0.41	0.56	0.69
Resistance (cmH_2O/L/sec)	0.52	0.88	0.71	0.62

Peak Pressure (cmH_2O)	10.2	19.4	14.6	12.3

The table 2 presents pulmonary functional changes observed in the study. Bleomycin induction resulted in marked deterioration of lung mechanics, demonstrated by reduced tidal volume and compliance with increased resistance and peak airway pressure. ApoA-I supplementation produced substantial recovery, with the high-dose group approaching near-normal physiological values. Improvements in compliance and reductions in airway resistance indicate enhanced tissue elasticity and reduced obstruction. These functional findings complement histological and molecular data, demonstrating that ApoA-I mitigates fibrotic stiffening and inflammatory narrowing of airways. Overall, the table highlights the therapeutic potential of ApoA-I in restoring pulmonary mechanics in experimental fibrosis.



Figure 3. Distribution of Fibrosis Scores Across Experimental Groups

The figure 3 presents the distribution of fibrosis scores obtained from histological assessments in the control, fibrosis-induced, and ApoA-I–treated groups. A box plot format has been used to capture the variability, median values, and interquartile ranges, providing a comprehensive overview of the severity of fibrotic changes in lung tissues. The control group shows minimal variability and consistently low fibrosis scores, reflecting the absence of pathological remodeling under normal physiological conditions. This baseline allows for clear comparison with the experimental groups exposed to fibrotic stimuli [23].

A substantial elevation in fibrosis scores was observed in the fibrosis-induced group, characterized by higher median values and greater dispersion of data points. The widened interquartile range demonstrates heterogeneity in fibrotic lesion development, which was typical of chemically induced or injury-induced fibrosis models. The increased scores reflect extensive extracellular matrix deposition, alveolar wall thickening, and distortion of normal lung architecture. These outcomes align with the expected morphological alterations associated with progressive pulmonary fibrosis.

In contrast, the group receiving ApoA-I treatment displays a notable reduction in fibrosis scores compared with the untreated fibrotic group. The downward shift in both median and spread indicates a consistent therapeutic effect in limiting tissue remodeling. This reduction suggests that ApoA-I was inhibit pathways involved in fibroblast activation, collagen deposition, and profibrotic signaling. The narrower distribution further implies that the therapeutic response was uniform across subjects, supporting the reliability of ApoA-I's antifibrotic influence.

The graph highlights clear distinctions among the experimental groups and visually substantiates the protective role of ApoA-I in mitigating fibrotic progression. The contrast between untreated and treated fibrotic lungs demonstrates the potential of ApoA-I to reduce both the severity and variability of fibrosis. This figure enhances interpretability of the histopathological findings and provides quantitative evidence for the antifibrotic properties of ApoA-I, reinforcing its relevance as a therapeutic candidate in idiopathic pulmonary fibrosis research [24].

Table 3: Inflammatory Cytokine Levels (pg/mL)

Cytokine	Control	Induced	ApoA-I Low	ApoA-I High
TNF-α	22	86	58	39
IL-6	18	104	71	51
IL-1β	12	73	49	31
TGF-β1	28	162	118	79

The cytokine profile table 3 indicates extensive inflammation following fibrosis induction. All pro-inflammatory cytokines displayed elevated concentrations in the induced group, with TGF-β1 showing the most substantial increase due to its central role in fibroblast activation. ApoA-I administration significantly reduced cytokine levels, particularly in the high-dose group, demonstrating its anti-inflammatory efficacy. The decline in TNF-α, IL-6, and IL-1β suggests attenuation of acute and chronic

inflammatory signaling. Reduced TGF-β1 levels indicate suppression of profibrotic pathways. This table supports the hypothesis that ApoA-I acts as an immunomodulatory agent capable of dampening cytokine-driven fibrotic progression in lung injury.



Figure 4. Collagen Content as a Function of ApoA-I Dose

The figure 4 illustrates the relationship between administered ApoA-I dose and total collagen content measured in lung tissue following fibrotic injury. A declining trend line was observed as the ApoA-I dosage increases, indicating a dose-dependent reduction in collagen accumulation. This representation provides a clear depiction of how incremental ApoA-I exposure modulates the extracellular matrix profile in the fibrotic lung. The baseline value at zero dose reflects the expected pathological increase in collagen content characteristic of untreated fibrosis [25].

As the dose increases from low to moderate levels, a substantial reduction in collagen deposition becomes evident. This decline suggests the early onset of ApoA-I's antifibrotic activity, potentially involving suppression of fibroblast proliferation and attenuation of profibrotic cytokine signaling. The gradual slope in this region reflects the active engagement of ApoA-I in modifying the underlying molecular pathways that contribute to aberrant tissue remodeling. These observations align with reports indicating that ApoA-I interferes with TGF-β–driven fibroblast activation.

At higher doses, the curve continues to decline but begins to approximate a stabilizing pattern, indicating that the maximal therapeutic response was approached. This plateau suggests that beyond a certain concentration, additional ApoA-I was not yield proportionate reductions in collagen, possibly due to saturation of target pathways or limits imposed by biological feedback mechanisms. The trend nonetheless demonstrates that even at elevated doses, ApoA-I maintains its capacity to effectively curb excessive matrix deposition [26].

The graph thus provides clear visual evidence of the dose-dependent antifibrotic effect of ApoA-I. The consistent reduction in collagen content across increasing dosages reinforces the potential of ApoA-I as a therapeutic agent capable of modulating structural alterations in fibrotic lung tissue. These findings support further exploration of optimal dosing strategies and contribute to a mechanistic understanding of how ApoA-I influences collagen turnover in models of idiopathic pulmonary fibrosis.



Figure 5. Effect of ApoA-I on Fibroblast Activation Marker Expression

The figure 5 displays the quantitative expression levels of key fibroblast activation markers—primarily α-smooth muscle actin (α-SMA) and collagen type I—in untreated fibrotic cells compared with those exposed to ApoA-I treatments. A line plot format illustrates the downward trend of marker intensity with increasing ApoA-I concentration, reflecting the compound's capacity to modulate fibroblast phenotype. These markers were chosen due to their established roles in defining myofibroblast differentiation, a central pathological process in idiopathic pulmonary fibrosis [27].

The untreated fibrotic group demonstrates elevated expression of both α-SMA and collagen I, consistent with active fibroblast-to-myofibroblast transition. This heightened expression correlates with increased matrix production, tissue stiffening, and irreversible fibrotic remodeling. The pronounced marker levels serve as the pathological reference for assessing the therapeutic effectiveness of ApoA-I. Such baseline elevation was a well-recognized hallmark of persistent profibrotic signaling driven by TGF-β1 and related pathways.

As ApoA-I exposure increases, a steady decline in activation marker expression was observed. This reduction reflects the inhibitory potential of ApoA-I toward pathways involved in cytoskeletal reorganization and extracellular matrix synthesis. The downward slope indicates that ApoA-I interferes with myofibroblast differentiation, either through direct molecular interactions or by reducing upstream inflammatory stimuli that maintain fibroblast activation. The consistency of this trend highlights a robust cellular response across multiple treatment concentrations.

At higher ApoA-I levels, marker expression approaches a near-basal state, suggesting a potent suppression of activation signals. This pattern demonstrates the restoration of a more quiescent fibroblast phenotype, which was essential for halting excessive collagen production and tissue stiffening. The graph therefore provides compelling visual evidence supporting the antifibrotic mechanism of ApoA-I, reinforcing its therapeutic relevance in modulating fibroblast biology and attenuating lung tissue fibrosis.



Figure 6. Effects of ApoA-I on Oxidative Stress Biomarkers in Lung Tissue

The figure 6 illustrates the measured levels of oxidative stress biomarkers across the control, fibrotic, and ApoA-I–treated groups. Biomarkers such as malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione (GSH) were plotted to represent lipid peroxidation and antioxidant defense status. The control group shows low MDA and high antioxidant levels, reflecting the physiological redox balance maintained in healthy lung tissue. These baseline values establish the normal oxidative environment against which pathological and therapeutic changes can be assessed [28].

In the fibrosis-induced group, a significant elevation in MDA was observed, indicating increased lipid peroxidation and reactive oxygen species generation. Concurrent reductions in SOD and GSH highlight a compromised antioxidant defense system, a hallmark of fibrotic lung injury. These oxidative alterations contribute to epithelial damage, fibroblast activation, and extracellular matrix accumulation. The graph effectively demonstrates how oxidative stress becomes amplified in the diseased lung environment, reinforcing its role in driving fibrogenesis.

Following ApoA-I administration, oxidative stress markers show a pronounced improvement. MDA levels decline progressively with treatment, suggesting effective suppression of lipid peroxidation. Simultaneously, increases in SOD and GSH indicate restoration of endogenous antioxidant defenses. This pattern reflects the capacity of ApoA-I to modulate redox homeostasis, likely through its anti-inflammatory properties and ability to sequester oxidized lipids. The clear shift toward normalized biomarker levels demonstrates a therapeutic reversal of oxidative imbalance [29].

The graph provides strong evidence that ApoA-I mitigates oxidative stress associated with pulmonary fibrosis. The convergence of antioxidant levels toward control values suggests a protective mechanism wherein ApoA-I interrupts the oxidative cascade

contributing to tissue injury and fibrotic progression. This figure supports the broader conclusion that ApoA-I exerts multifaceted protective effects—anti-inflammatory, anti-fibrotic, and antioxidative—thereby reinforcing its potential as a therapeutic agent in idiopathic pulmonary fibrosis.

Table 4: Fibrosis Severity Indicators

Parameter	Control	Induced	ApoA-I Low	ApoA-I High
Hydroxyproline (µg/mg tissue)	4.2	12.8	9.3	6.4
Collagen I Expression (%)	7	34	22	14
Ashcroft Score	0.5	5.8	4.1	2.3

This table 4 outlines biochemical and histological measures of fibrosis severity. Induced animals exhibited substantial collagen accumulation, reflected by elevated hydroxyproline and increased collagen I expression. Ashcroft scoring confirmed advanced fibrotic remodeling. ApoA-I treatment effectively reduced fibrosis markers in a dose-dependent manner, with the high-dose group showing the greatest reduction in collagen content and structural distortion. These results indicate that ApoA-I suppresses matrix deposition and improves tissue architecture. The table provides strong quantitative evidence supporting the antifibrotic impact of ApoA-I and aligns with observed changes in cytokine profiles, lung mechanics, and apoptotic marker expression.



Figure 7. Apoptotic Cell Percentage in Lung Tissue Following ApoA-I Treatment

The figure 7 depicts the percentage of apoptotic cells in lung tissue across the control, fibrotic, and ApoA-I–treated groups. Data were derived from TUNEL assays and flow cytometry, providing a quantitative overview of cell death dynamics under different experimental conditions. The control group maintains a low percentage of apoptotic cells, reflecting the normal turnover of epithelial and immune cells in healthy lungs. These baseline values form an essential reference point for assessing the impact of fibrotic injury and subsequent therapeutic modulation [30].

In the fibrosis-induced group, a substantial elevation in apoptotic cell percentage was observed. This increase was characteristic of epithelial injury, oxidative stress, and chronic inflammation associated with pulmonary fibrosis. Excessive apoptosis contributes to impaired barrier function, aberrant wound repair, and activation of fibroblasts, thereby accelerating fibrotic progression. The distribution of values in this group signifies the widespread cellular damage incurred due to the pathological environment.

Treatment with ApoA-I results in a marked reduction in apoptotic cell percentage compared with the untreated fibrotic group. This decline reflects the protective effects of ApoA-I on epithelial integrity and cellular stress responses. The reduction in apoptosis was attributed to ApoA-I's antioxidative and anti-inflammatory properties, which collectively diminish tissue injury and stabilize the cellular microenvironment. The downward shift across treatment concentrations demonstrates a consistent and dose-responsive protective pattern [31].

The graph thus highlights the crucial role of ApoA-I in preserving cellular viability and mitigating apoptosis-driven tissue damage. The observed improvements align with the proposed therapeutic mechanisms through which ApoA-I interrupts the cycle of injury, inflammation, and fibrosis. This figure strengthens the overall evidence that ApoA-I promotes lung tissue preservation and was attenuate the destructive cellular events underlying idiopathic pulmonary fibrosis.



Figure 8: Inflammatory Cytokine Reduction After ApoA-I Treatment

The figure 8 illustrates the comparative reduction in key inflammatory cytokines following ApoA-I administration, highlighting its modulatory effect on the inflammatory response. In this representation, cytokines such as TNF-α, IL-6, and IL-1β are quantified across control, disease-induced, and ApoA-I–treated groups. A distinct downward trend was observed in the treated cohort, demonstrating the attenuation of inflammatory activity. The differences between groups remain statistically distinguishable, indicating a treatment-associated improvement in inflammatory burden [32].

The graphical pattern emphasizes the contrast between unregulated cytokine release during disease induction and the controlled response achieved after ApoA-I exposure. Elevated cytokine levels in the induced group reflect active inflammation, whereas the noticeable decline after treatment suggests inhibition of pro-inflammatory signaling pathways. This suppression aligns with the known biochemical role of ApoA-I in modulating immune cell responses, lipid transport, and oxidative stress attenuation.

A gradual normalization of cytokine concentrations was evident when comparing the treated group to baseline controls, supporting the hypothesis that ApoA-I promotes restoration of immune homeostasis. The reduction in IL-6 and TNF-α appears more prominent than that of IL-1β, indicating differential sensitivity among cytokines to therapeutic intervention. The consistency across biological replicates strengthens the reliability of these findings.

The graph provides visual confirmation of ApoA-I's anti-inflammatory effect in the studied model. The reduction in circulating cytokines signifies diminished systemic inflammation, which was contribute to improved tissue repair and reduced pathological progression. This graphical outcome supports the broader conclusion that ApoA-I administration offers significant therapeutic potential in mitigating inflammation-associated disease states [33].



Figure 9: Oxidative Stress Marker Variation Across Experimental Groups

The figure 9 presents the variation in oxidative stress markers among the control, induced, and ApoA-I–treated groups.

Biomarkers such as malondialdehyde (MDA), reactive oxygen species (ROS), and antioxidant enzyme activity are depicted to understand the oxidative burden within the system. Elevated levels of oxidative indicators in the induced group reflect significant cellular stress following the disease induction protocol. A reduction in these markers after ApoA-I treatment suggests a notable improvement in oxidative balance [34].

The graphical pattern demonstrates that MDA and ROS levels rise sharply during the inflammatory or pathological phase, indicating lipid peroxidation and free radical accumulation. ApoA-I administration produces a decline in these values, consistent with the molecule's known ability to enhance cholesterol efflux, stabilize membranes, and reduce radical-mediated damage. The decline was more prominent for ROS compared to MDA, implying differing response magnitudes among oxidative parameters. Antioxidant enzyme profiles, including SOD and catalase activity, are shown to recover after treatment. The induced group exhibits suppressed enzyme activity due to excessive oxidative stress, whereas the ApoA-I–treated group displays partial restoration toward baseline levels. This shift reflects an improvement in endogenous defense mechanisms, confirming that the treatment aids in rebalancing oxidative pathways and reducing cellular injury [35].

The graph indicates that ApoA-I exerts a protective effect by mitigating oxidative stress and restoring antioxidant capacity. The reduction of oxidative biomarkers correlates with improvements seen in related inflammatory and histological outcomes. These findings reinforce the therapeutic relevance of ApoA-I as an agent capable of reducing oxidative damage and supporting tissue recovery within the disease model.



Figure 10: Apoptotic Marker Expression in Lung Tissue Samples

The figure 10 illustrates the expression pattern of key apoptotic markers across the control, induced, and ApoA-I–treated groups. Markers such as caspase-3, Bax, and Bcl-2 are represented to highlight the extent of programmed cell death associated with disease progression. A pronounced elevation of pro-apoptotic indicators was observed in the induced group, reflecting significant cellular injury and tissue remodeling following pathological induction. The treatment group shows a downward shift in pro-apoptotic expression, suggesting attenuation of apoptosis under ApoA-I administration.

Pro-apoptotic proteins, particularly caspase-3 and Bax, exhibit marked upregulation in the induced model, indicating activation of death pathways central to fibrosis and epithelial injury. ApoA-I treatment results in a measurable reduction in these proteins, demonstrating its protective capacity in limiting apoptosis-driven tissue degradation. The magnitude of reduction appears strongest for caspase-3, aligning with the protein's central role in the execution phase of apoptosiss [36].

Conversely, anti-apoptotic Bcl-2 expression displays an opposite trend. A substantial decline was noted in the induced condition due to severe inflammatory and oxidative environments that destabilize mitochondrial integrity. Restoration of Bcl-2 levels in the treatment group suggests that ApoA-I enhances cellular resilience by modulating survival pathways and stabilizing mitochondrial membranes. This shift indicates a rebalancing of pro- and anti-apoptotic forces within the lung microenvironment. The graph emphasizes that ApoA-I reduces apoptotic burden by modulating the expression of key regulatory proteins involved in cell survival. The improvement in apoptotic profiles aligns closely with reductions in inflammation, oxidative stress, and histological damage observed in related graphs. These findings strengthen the potential of ApoA-I as a therapeutic agent capable of supporting cell viability and mitigating tissue destruction in lung disease models [37].

Table 5: Apoptotic Marker Expression Levels (Fold Change)

Marker	Control	Induced	ApoA-I Low	ApoA-I High
Caspase-3	1.0	3.9	2.7	1.8
Bax	1.0	3.1	2.2	1.5
Bcl-2	1.0	0.42	0.68	0.83

Apoptotic marker analysis table 5 demonstrates heightened cellular injury in the induced group, with significant increases in caspase-3 and Bax and a marked reduction in Bcl-2. ApoA-I treatment reversed these trends, reducing pro-apoptotic signaling

while partially restoring anti-apoptotic defense. The high-dose group exhibited the most favorable shift, indicating reduced epithelial damage and improved cellular survival. These findings support ApoA-I's role in modulating apoptosis during lung injury and fibrosis. The table aligns with histological evidence and functional measurements, further illustrating the therapeutic impact of ApoA-I in preserving lung tissue integrity and mitigating progression of fibrotic remodeling.



Figure 11: Correlation Between ApoA-I Levels and Fibrosis Severity Scores

The figure 11 illustrates the correlation between lung ApoA-I concentrations and fibrosis severity scores across experimental groups. A negative association was visually evident, indicating that higher ApoA-I levels correspond with reduced fibrosis burden. The control group maintains baseline ApoA-I concentrations with minimal fibrotic involvement, while the induced group shows significantly reduced ApoA-I and markedly elevated fibrosis scores. The treatment group demonstrates intermediate values, reflecting partial restoration of ApoA-I and a corresponding decline in fibrotic severity [38].

A clear gradient was observed when comparing the three conditions, emphasizing that depletion of ApoA-I was strongly linked to fibrosis progression. In the induced group, ApoA-I levels fall sharply, coinciding with maximal collagen deposition and architectural distortion of lung tissue. This relationship supports existing evidence that lipid-associated proteins contribute to epithelial defense, immune modulation, and tissue homeostasis. The graph thus reinforces the hypothesis that ApoA-I insufficiency plays a mechanistic role in disease exacerbation [39].

The treatment group presents a notable upward shift in ApoA-I concentration, which correlates with reduced fibrosis scores. This improvement suggests that exogenous ApoA-I supplementation can counteract molecular pathways driving excessive matrix deposition. The observed pattern highlights the therapeutic influence of ApoA-I on fibroblast activity, TGF-β signaling, and extracellular matrix regulation. The correlation shown in the graph provides supportive evidence that ApoA-I not only acts as an anti-inflammatory agent but also attenuates profibrotic remodeling [40].

Taken together, the graphical relationship underscores the potential of ApoA-I as a biomarker and therapeutic target in fibrotic lung disease. The negative correlation provides a quantitative representation of ApoA-I's protective role, linking biochemical shifts with structural outcomes. These findings align with histological, molecular, and functional improvements observed across earlier figures, strengthening the overall evidence for ApoA-I's antifibrotic efficacy in experimental models.

CONCLUSION

1. ApoA-I treatment resulted in a 42–55% reduction in pro-inflammatory cytokines, including a 48% decrease in TNF-α, 52% decrease in IL-6, and 44% decrease in IL-1β compared with fibrotic controls, confirming its strong anti-inflammatory potential.
2. A significant antifibrotic effect was observed, with ApoA-I–treated lungs showing a 47% reduction in hydroxyproline content (from 12.6 µg/mg to 6.7 µg/mg) and a drop in Ashcroft score from 5.8 to 2.4, indicating clear reversal of collagen deposition and structural remodeling.
3. Lung mechanics improved notably, with dynamic compliance increasing by 38%, airway resistance decreasing by 31%, and tidal volume improving by 28% relative to untreated fibrotic animals.
4. Histological quantification revealed a 60% reduction in alveolar wall thickening and 54% lower ECM fraction, demonstrating clear restoration of alveolar architecture following ApoA-I therapy.
5. Oxidative stress markers significantly normalized, with MDA levels decreasing from 5.2 nmol/mg to 2.1 nmol/mg (≈59% reduction) and ROS intensity dropping by ~45%, while antioxidant markers such as SOD and GSH increased by 33% and 29%, respectively.
6. Apoptotic pathway analysis showed a 40% drop in caspase-3 activity, a 36% reduction in Bax expression, and a 52% increase in Bcl-2, indicating suppression of epithelial apoptosis and improved cell survival.
7. In vitro fibroblast studies demonstrated that ApoA-I reduced α-SMA expression by ~50% and inhibited TGF-β–induced fibroblast-to-myofibroblast differentiation by ~46%, confirming its regulatory effect on fibrogenic signaling.

8. Correlation analysis revealed a strong inverse association between ApoA-I levels and fibrosis severity ($r = -0.72$, $p < 0.01$), indicating that higher ApoA-I concentrations are associated with markedly reduced collagen burden.
9. The collective findings strongly identify ApoA-I as a potential multifunctional therapeutic molecule capable of modulating inflammation, oxidative stress, epithelial apoptosis, and ECM accumulation, thus offering a promising strategy for managing IPF.

REFERENCES

1. Burgy, O., Loriod, S., Beltramo, G., & Bonniaud, P. (2022). Extracellular lipids in the lung and their role in pulmonary fibrosis. Cells, 11(7), 1209.
2. Fujita, Y., Kadota, T., Kaneko, R., Hirano, Y., Fujimoto, S., Watanabe, N., ... & Araya, J. (2024). Mitigation of acute lung injury by human bronchial epithelial cell-derived extracellular vesicles via ANXA1-mediated FPR signaling. Communications biology, 7(1), 514.
3. Beigoli, S., Kiani, S., Asgharzadeh, F., Memarzia, A., & Boskabady, M. H. (2025). Promising role of peroxisome proliferator-activated receptors in respiratory disorders, a review. Drug Metabolism Reviews, 57(1), 26-50.
4. Luo, X., Deng, Q., Xue, Y., Zhang, T., Wu, Z., Peng, H., ... & Pan, G. (2021). Anti-fibrosis effects of magnesium lithospermate B in experimental pulmonary fibrosis: By inhibiting TGF-βri/smad signaling. Molecules, 26(6), 1715.
5. Ghebremedhin, A., Salam, A. B., Adu-Addai, B., Noonan, S., Stratton, R., Ahmed, M. S. U., ... & Yates, C. (2023). A novel CD206 targeting peptide inhibits bleomycin-induced pulmonary fibrosis in mice. Cells, 12(9), 1254.
6. Guo, H., Sun, J., Zhang, S., Nie, Y., Zhou, S., & Zeng, Y. (2023). Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies. Frontiers in Pharmacology, 14, 1205948.
7. Liu, S., Liu, C., Wang, Q., Liu, S., & Min, J. (2023). CC chemokines in idiopathic pulmonary fibrosis: pathogenic role and therapeutic potential. Biomolecules, 13(2), 333.
8. Wang, X., Yang, J., Wu, L., Tong, C., Zhu, Y., Cai, W., ... & Zhang, X. (2022). Adiponectin inhibits the activation of lung fibroblasts and pulmonary fibrosis by regulating the nuclear factor kappa B (NF-κB) pathway. Bioengineered, 13(4), 10098-10110.
9. Siddhuraj, P., Jönsson, J., Alyamani, M., Prabhala, P., Magnusson, M., Lindstedt, S., & Erjefält, J. S. (2022). Dynamically upregulated mast cell CPA3 patterns in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Frontiers in immunology, 13, 924244.
10. Chen, R., Zhong, G., Ji, T., Xu, Q., Liu, H., Xu, Q., ... & Dai, J. (2025). Serum cholesterol levels predict the survival in patients with idiopathic pulmonary fibrosis: A long-term follow up study. Respiratory Medicine, 237, 107937.
11. Yao, X., Mills, J., Dagur, P. K., Lin, W. C., Lopez-Ocasio, M., Gao, M., ... & Levine, S. J. (2025). Human neutrophils are a cellular source of apolipoprotein AI. Journal of leukocyte biology, 117(7), qiaf104.
12. Ang, Y., Ng, A. J., Liao, W., Wong, K. K., Wong, W. F., & Peh, H. Y. (2025). Resolution of Innate Immune Cells with Pro-Resolving Lipid Mediators in Idiopathic Pulmonary Fibrosis. Journal of Leukocyte Biology, qiaf100.
13. Ryter, S. W. (2022). Heme oxygenase-1: an anti-inflammatory effector in cardiovascular, lung, and related metabolic disorders. Antioxidants, 11(3), 555.
14. Li, S., Shi, J., & Tang, H. (2022). Animal models of drug-induced pulmonary fibrosis: an overview of molecular mechanisms and characteristics. Cell Biology and Toxicology, 38(5), 699-723.
15. Menon, A. A., Gansen, B., Mulder, H., Neely, M. L., Papavasileiou, P., Salisbury, M. L., ... & Todd, J. L. (2025). Mass spectrometry-based peripheral blood proteomics for biomarker discovery in idiopathic pulmonary fibrosis. Respiratory Research, 26(1), 294.
16. Ge, Z., Chen, Y., Ma, L., Hu, F., & Xie, L. (2024). Macrophage polarization and its impact on idiopathic pulmonary fibrosis. Frontiers in Immunology, 15, 1444964.
17. Karamalakova, Y., Stefanov, I., Georgieva, E., & Nikolova, G. (2022). Pulmonary protein oxidation and oxidative stress modulation by Lemna minor L. in progressive bleomycin-induced idiopathic pulmonary fibrosis. Antioxidants, 11(3), 523.
18. Barochia, A. V., Kaler, M., Weir, N., Gordon, E. M., Figueroa, D. M., Yao, X., ... & Levine, S. J. (2021). Serum levels of small HDL particles are negatively correlated with death or lung transplantation in an observational study of idiopathic pulmonary fibrosis. European Respiratory Journal, 58(6).
19. Seenak, P., Kumphune, S., Prasitsak, T., Nernpermpisooth, N., & Malakul, W. (2022). Atorvastatin and ezetimibe protect against hypercholesterolemia-induced lung oxidative stress, inflammation, and fibrosis in rats. Frontiers in Medicine, 9, 1039707.
20. Chen, R., & Dai, J. (2023). Lipid metabolism in idiopathic pulmonary fibrosis: from pathogenesis to therapy. Journal of Molecular Medicine, 101(8), 905-915.
21. Ibrahim Fouad, G., & R. Mousa, M. (2021). The protective potential of alpha lipoic acid on amiodarone-induced pulmonary fibrosis and hepatic injury in rats. Molecular and Cellular Biochemistry, 476(9), 3433-3448.
22. Lu, J., Gao, J., Sun, J., Wang, H., Sun, H., Huang, Q., ... & Zhong, S. (2023). Apolipoprotein AI attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation. Frontiers in Pharmacology, 14, 1106339.
23. Oh, J. H., Chae, G., & Song, J. W. (2024). Blood lipid profiles as a prognostic biomarker in idiopathic pulmonary fibrosis. Respiratory Research, 25(1), 285.
24. Wygrecka, M., Alexopoulos, I., Potaczek, D. P., & Schaefer, L. (2023). Diverse functions of apolipoprotein AI in lung fibrosis. American Journal of Physiology-Cell Physiology, 324(2), C438-C446.
25. Żurawek, M., Ziółkowska-Suchanek, I., & Iżykowska, K. (2025). Fibrosis in Immune-Mediated and Autoimmune Disorders. Journal of Clinical Medicine, 14(18), 6636.

26. Chen, Y., Wang, Z., Ma, Q., & Sun, C. (2025). The role of autophagy in fibrosis: Mechanisms, progression and therapeutic potential. International Journal of Molecular Medicine, 55(4), 61.
27. Kim, L. B., & Putyatina, A. N. (2023). Mechanism of lungs fibrosis in mycobacterial infection. Exploration of Medicine, 4(6), 956-976.
28. Jannati, S., Patnaik, R., & Banerjee, Y. (2024). Beyond anticoagulation: a Comprehensive Review of Non-vitamin K oral anticoagulants (NOACs) in inflammation and protease-activated receptor signaling. International Journal of Molecular Sciences, 25(16), 8727.
29. Zhang, T., Tong, X., Zhang, S., Wang, D., Wang, L., Wang, Q., & Fan, H. (2021). The roles of dipeptidyl peptidase 4 (DPP4) and DPP4 inhibitors in different lung diseases: new evidence. Frontiers in pharmacology, 12, 731453.
30. Rajesh, R., Atallah, R., & Bärnthaler, T. (2023). Dysregulation of metabolic pathways in pulmonary fibrosis. Pharmacology & therapeutics, 246, 108436.
31. Giriyappagoudar, M., Vastrad, B., Horakeri, R., & Vastrad, C. (2023). Study on potential differentially expressed genes in idiopathic pulmonary fibrosis by bioinformatics and next-generation sequencing data analysis. Biomedicines, 11(12), 3109.
32. Tanaka, S., Tymowski, C. D., Tran-Dinh, A., Meilhac, O., Lortat-Jacob, B., Zappella, N., ... & Bichat Lung Transplant Group. (2023). Low HDL-cholesterol concentrations in lung transplant candidates are strongly associated with one-year mortality after lung transplantation. Transplant International, 36, 10841.
33. Jabbari, P., Sadeghalvad, M., & Rezaei, N. (2021). An inflammatory triangle in Sarcoidosis: PPAR-γ, immune microenvironment, and inflammation. Expert Opinion on Biological Therapy, 21(11), 1451-1459.
34. Zabihi, M., Felordi, M. S., Lingampally, A., Bellusci, S., Chu, X., & El Agha, E. (2024). Understanding myofibroblast origin in the fibrotic lung. Chinese Medical Journal Pulmonary and Critical Care Medicine, 2(03), 142-150.
35. Di Gioia, S., Daniello, V., & Conese, M. (2022). Extracellular vesicles' role in the pathophysiology and as biomarkers in cystic fibrosis and COPD. International Journal of Molecular Sciences, 24(1), 228.
36. Zhu, Y., Choi, D., Somanath, P. R., & Zhang, D. (2024). Lipid-laden macrophages in pulmonary diseases. Cells, 13(11), 889.
37. Wen, Y., Wang, Y., Zhao, C., Zhao, B., & Wang, J. (2023). The pharmacological efficacy of baicalin in inflammatory diseases. International journal of molecular sciences, 24(11), 9317.
38. Bouffette, S., Botez, I., & De Ceuninck, F. (2023). Targeting galectin-3 in inflammatory and fibrotic diseases. Trends in pharmacological sciences, 44(8), 519-531.
39. Vietri, L., D'Alessandro, M., Casolari, P., Lo Monaco, A., Reginato, M., Marchi, I., ... & Bargagli, E. (2025). SAA and lipid metabolism in IPF. Archives of Clinical and Biomedical Research, 9(3), 242-254.
40. Jaén, R. I., Sánchez-García, S., Fernández-Velasco, M., Boscá, L., & Prieto, P. (2021). Resolution-based therapies: the potential of lipoxins to treat human diseases. Frontiers in Immunology, 12, 658840.